Every material Form 8-K TherapeuticsMD, Inc. has filed with the SEC since March 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TherapeuticsMD reported second quarter 2026 results, with net income from continuing operations of $164 thousand, down from $545 thousand a year earlier, and license revenue of $869 thousand, down from $952 thousand. The company continues to explore strategic alternatives, including a possible acquisition, merger, or sale of assets, but says there is no assurance of a transaction and has set no timetable.
Net income from continuing operations: $164 thousand in Q2 2026 vs. $545 thousand in Q2 2025.
License revenue: $869 thousand in Q2 2026 vs. $952 thousand in Q2 2025, attributed to changes in sales of licensed products.
Total operating expenses rose $38 thousand, or 2.3%, to $1.7 million, mainly due to higher general and administrative expenses and patent write-offs.
Cash and cash equivalents were $9.2 million as of June 30, 2026.
TherapeuticsMD reported net income from continuing operations of $103 thousand for the quarter ended March 31, 2026, compared with a net loss of $636 thousand a year earlier. License revenue rose to $724 thousand, mainly from the Mayne License Agreement, while operating expenses fell 13.6%. The company also said it is still exploring strategic alternatives, including a possible acquisition, merger, or sale of assets, with no timetable set.
Net income from continuing operations was $103 thousand, versus a net loss of $636 thousand in Q1 2025.
License revenue was $724 thousand, up $331 thousand from $393 thousand in Q1 2025.
Total operating expenses were $1,447 thousand, down $227 thousand or 13.6% from $1,674 thousand.
Cash and cash equivalents totaled $8.4 million as of March 31, 2026; the strategic review has no set timetable.
TherapeuticsMD reported full-year 2025 results in a press release furnished on Form 8-K. The net loss from continuing operations narrowed to $0.7 million from $2.3 million in 2024, as license revenue rose 71.6% to $3.0 million and operating expenses fell 5.9% to $7.4 million. The company said it continues to explore strategic alternatives, including a possible acquisition, merger or sale of assets, but has set no timetable and gave no assurance of a transaction.
Net loss from continuing operations was $(0.7) million, or $(0.06) per share, versus $(2.3) million, or $(0.20) per share, in 2024.
License revenue, primarily from the Mayne License Agreement, was $3.0 million, up from $1.8 million in 2024.
Total operating expenses were $7.4 million, down $0.5 million, mainly due to lower impairment charges.
Cash and cash equivalents were $7.5 million as of December 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TherapeuticsMD, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →